MX369874B - Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. - Google Patents

Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.

Info

Publication number
MX369874B
MX369874B MX2013014040A MX2013014040A MX369874B MX 369874 B MX369874 B MX 369874B MX 2013014040 A MX2013014040 A MX 2013014040A MX 2013014040 A MX2013014040 A MX 2013014040A MX 369874 B MX369874 B MX 369874B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
gel
inhibiting
drug
treatment
Prior art date
Application number
MX2013014040A
Other languages
English (en)
Other versions
MX2013014040A (es
Inventor
Daniel Walls Flores Oliver
Astrid Salto Rivera Reyna
Rodríguez Hernández Ramón
Arturo Moreno Hinojosa Raúl
Original Assignee
Laboratorios Liomont S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53493336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369874(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Liomont S A De C V filed Critical Laboratorios Liomont S A De C V
Priority to MX2013014040A priority Critical patent/MX369874B/es
Priority to PCT/IB2014/066410 priority patent/WO2015101849A1/es
Publication of MX2013014040A publication Critical patent/MX2013014040A/es
Publication of MX369874B publication Critical patent/MX369874B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica, inhibidora de la enzima fosfodiesterasa que contiene 1 - ((3 - (6,7 - dihidro - 1 - metil - 7 - oxo - 3 - propil - 1 H-pirazolo (4,3 - d) pirimidin - 5 - il) - 4 - etoxifenil) sulfonil) - 4- met ilpiperazina, como agente activo asociado con uno o mas excipientes farmacéuticamente aceptables; en la forma farmacéutica en sobres de gel o en un dispositivito dosificador.
MX2013014040A 2013-11-29 2013-11-29 Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. MX369874B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2013014040A MX369874B (es) 2013-11-29 2013-11-29 Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.
PCT/IB2014/066410 WO2015101849A1 (es) 2013-11-29 2014-11-28 Composición farmacéutica para el tratamiento de la disfunción eréctil a base de un fármaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013014040A MX369874B (es) 2013-11-29 2013-11-29 Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.

Publications (2)

Publication Number Publication Date
MX2013014040A MX2013014040A (es) 2015-05-28
MX369874B true MX369874B (es) 2019-11-22

Family

ID=53493336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014040A MX369874B (es) 2013-11-29 2013-11-29 Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.

Country Status (2)

Country Link
MX (1) MX369874B (es)
WO (1) WO2015101849A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2120570B1 (en) * 2007-02-12 2012-05-16 DMI Biosciences, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
DE102009033396A1 (de) * 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
ES2555353T3 (es) * 2010-08-02 2015-12-30 Nch Corporation Lavadora de piezas y método para lavar piezas

Also Published As

Publication number Publication date
MX2013014040A (es) 2015-05-28
WO2015101849A1 (es) 2015-07-09

Similar Documents

Publication Publication Date Title
SG11201803699YA (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
MY187047A (en) Selective pyy compounds and uses thereof
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
PH12014501991B1 (en) Phenicol antibacterials
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12015502632A1 (en) Cxcr7 receptor modulators
MX2020012989A (es) Agente terapeutico para la fibrosis.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
MX369874B (es) Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
UA88315U (en) Antibacterial composition
UA90602U (uk) Фармацевтична композиція комбінованої дії
RU2015111612A (ru) Фармацевтическая композиция на основе 3-(3,5-Диметилпиразол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства

Legal Events

Date Code Title Description
FG Grant or registration